While still not a fan of recreational marijuana, Sen. Orrin Hatch (R-Utah) is teaming up with Sen. Brian Schatz (D-Hawaii) to introduce the Marijuana Effective Drug Study Act of 2017, otherwise known as the MEDS Act, in conjunction with bi-partisan support from co-sponsors Senator Chris Coons (D-DE), Senator Cory Gardner (R-CO), and Senator Thom Tillis (R-NC), which intends to expand research into the benefits of medical marijuana.
In an official press release from his office, Hatch not only showed that he was willing to make this bill a bipartisan effort, he attempted to show the youngsters that he was hip to the lingo – by making some very, very bad puns.
“It’s high time to address research into medical marijuana,” Hatch said. “Our country has experimented with a variety of state solutions without properly delving into the weeds on the effectiveness, safety, dosing, administration, and quality of medical marijuana. All the while, the federal government strains to enforce regulations that sometimes do more harm than good. To be blunt, we need to remove the administrative barriers preventing legitimate research into medical marijuana, which is why I’ve decided to roll out the MEDS Act.”
“I urge my colleagues to join Senator Schatz and me in our joint effort to help thousands of Americans suffering from a wide-range of diseases and disorders. In a Washington at war with itself, I have high hopes that this bipartisan initiative can be a kumbaya moment for both parties.”
So many groans aside, the benefits of the MEDS act, as shown in the press release are;
• Encourage more research on the potential medical uses of marijuana by streamlining the research registration process, without imposing a scheduling determination on the Drug Enforcement Agency (DEA).
• Make marijuana more available for legitimate scientific and medical research and the commercial production of any FDA-approved drugs derived from marijuana.
Retain important checks to protect against diversion or abuse of the controlled marijuana substances.
• Require the National Institute on Drug Abuse (NIDA) to develop and publish recommendations for good manufacturing practices for growing and producing marijuana for research.
• Require the Attorney General to increase the national marijuana quota in a timely manner to meet the changing medical, scientific, and industrial needs for marijuana.
• Codify the administration’s decision to terminate the Public Health Service and its review of proposals for medical research on marijuana.Prevent the Department of Health and Human Services from instituting any other marijuana-specific protocol reviews, other than the voluntary review that a researcher can request from National Institutes of Health (NIH) in order to access the expedited DEA registration process.